CPA
CARM

Cowen Prime Advisors’s Carisma Therapeutics CARM Stock Holding History

Cowen Prime Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-35
Closed -$2K – 231
2015
Q3 		$2K Sell
35
-50
-59% -$3.08K ﹤0.01% 219
2015
Q2 		$5K Buy
+85
New +$12K ﹤0.01% 222

Other funds holding CARM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return

Cowen Prime Advisors's CARM Position: Q4 2015 in Review

Cowen Prime Advisors sold out of Carisma Therapeutics (CARM) in Q4 2015, closing a stake of 35 shares — an estimated $2K sold.

Cowen Prime Advisors first reported a position in CARM in Q2 2015 and held it in 2 quarters. The position peaked at $5K in Q2 2015. 29 funds tracked by Wall St. Rank hold CARM as of Q4 2015.

  • Cowen Prime Advisors reported no remaining Carisma Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Cowen Prime Advisors sold 35 Carisma Therapeutics shares in Q4 2015, an estimated $2K.
  • Cowen Prime Advisors first reported a position in Carisma Therapeutics in Q2 2015 and held it in 2 quarters.
  • Cowen Prime Advisors's Carisma Therapeutics position peaked at $5K in Q2 2015.
  • 29 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2015.

Based on Cowen Prime Advisors's 13F filing for Q4 2015, filed 9 Feb 2016.